33 / 34
ADVANTAGES
LIMITATIONS
NIVOLUMAB
- OS
- Low toxicity rates
- Duration of response
- QoL
- Poor risk?
- Response Rate
- Rate of PD, time to resp
- PFS
- No brain mets
CABOZANTINIB
- Positive 3 objectives (RR, PFS, OS)
- Bone mets
- Brain mets included
- Similar RR than Nivo
- Toxicity
AXITINIB
- RR (dose tritation)
- Pure second-line trial
- Toxicity
- Activity Favorable group
- No impact OS
LENVATINIB + EVEROLIMUS
- Response rate
- High tumor burden
- Low PD
- Median time to response
- Toxicity
- Phase II
2
nd
line options:
Pros & Con